{"analyses":[{"ciLowerLimit":"0.51","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.81","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0002","paramType":"Hazard Ratio (HR)","paramValue":"0.64","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.96","upperLimit":"4.24","value":"3.94"},{"groupId":"OG001","lowerLimit":"2.23","upperLimit":"2.92","value":"2.60"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"316"},{"groupId":"OG001","value":"156"}],"units":"Participants"}],"description":"To further evaluate the robustness of the PFS analysis, Lilly established an independent review of PFS to assess the potential for investigator bias in the determination of objective PD. PFS was measured from the date of randomization to the first date of objectively determined PD or death. For patients alive as of the data cutoff date and who did not have PD, PFS was censored at the date of the last objective tumor assessment. PD was determined using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. PD = 20% increase in sum of longest diameter of target lesions.","dispersionType":"95% Confidence Interval","groups":[{"description":"pemetrexed and cisplatin followed by maintenance pemetrexed plus best supportive care","id":"OG000","title":"Pemetrexed + Cisplatin Followed by Maintenance Pemetrexed"},{"description":"pemetrexed + cisplatin followed by placebo plus best supportive care","id":"OG001","title":"Pemetrexed + Cisplatin Followed by Placebo"}],"paramType":"MEDIAN","populationDescription":"Randomized participants with reviewable scan--(316/359 \\[88%\\] Maintenance arm and 156/180 \\[87%\\] Placebo comparator arm. The majority of unread scans (12.4%) were due to participants not completing 1 cycle of treatment by the data cutoff date (30 June 2010).","reportingStatus":"POSTED","timeFrame":"Date of randomization to first date of measured PD or date of death from any cause (up to 19.3 months)","title":"Independently-assessed Objective Progression-free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"months"}